Navigation Links
Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
Date:4/20/2011

MALVERN, Pa., April 20, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Deutsche Bank 36th Annual Health Care Conference during May 2-4, 2011 at the InterContinental Boston.  Mr. Jim Fickenscher, Chief Financial Officer, is scheduled to present an overview of the Company and its product pipeline at 1:30 p.m. ET on Tuesday, May 3, 2011.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for ninety days after the event.

About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 2011 Deutsche Bank 36th Annual Health Care Conference; and products in development for Peyronie's disease and Frozen Shoulder syndrome; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010, which is on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
2. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
3. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
4. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
6. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
7. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
9. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
10. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has announced ... report to their offering. ... The global travel vaccines market to grow at a ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the sales of various vaccines ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic Lasers ... report, "Australia Ophthalmic Lasers Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segements - Excimer Lasers, Femtosecond Lasers and YAG Lasers. ... shares data for each of these market segements, and ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... 08, 2016 , ... STAT courier is pleased to announce that due to ... they are expanding their presence in Dallas. One of the most exciting parts for ... jobs to the Dallas and Forth Worth market. STAT takes pride in treating their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the ... Series B led by Canvas Ventures . Other investors include Nokia Growth Partners ... mobile platform to serve more consumers who are managing chronic conditions or ...
Breaking Medicine News(10 mins):